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Abstract: Adenosine receptors (ARs), like many otherGprotein-coupledreceptors (GPCRs), are 
targets of primary interest indrug design. However, one of the main limits for the development of 
drugs for this class of GPCRs is the complex selectivity profile usually displayed by ligands. 
Numerous efforts have been madefor clarifying the selectivity of ARs, leading to the development 
of many ligand-based models. The structure of the AR subtype A1 (A1AR) has been recently 
solved,providing important structural insights. In the present work, we rationalized the selectivity 
profile of two selective A1AR and A2AAR antagonists, investigating their recognition trajectories 
obtained by Supervised Molecular Dynamics from an unbound state and monitoring the role of the 
water molecules in the binding site. 
Keywords: GPCRs; adenosine receptors; selectivity; A1AR; A2AAR; antagonist;moleculardynamics 
(MD); supervised molecular dynamics (SuMD) 
 
1. Introduction 
Adenosine receptors(ARs)are class A G protein-coupled receptors(GPCRs) that bind the 
endogenous agonist adenosine.ARs are composed of foursubtypes: A1, A2A, A2B, A3. While A1 and 
A3ARs (which share 49% of a sequence identity) are preferentially coupled to Gαiproteinsand 
therefore inhibit the adenylatecyclase, A2A and A2BARs (sharing 59% of a sequence identity) 
stimulatethis enzyme, as being coupled to Gαs proteins[1]. Several ARs antagonists are in clinical 
trials for various diseases. With regards to A2AAR,istradefyllinehas been recently approved for 
Parkinson’sdisease (NCT02610231)[2], PBF-509 is in phase I/II trials for non-small cell lung cancer 
(NCT02403193), and CPI-144 is in phase I trials for various cancer types (NTC02655822). PBF-680, on 
the other hand, is the only A1 AR antagonist inclinical phase II, for the treatment of Asthma 
(NTC02635945)[3]. 
One of thedifficulties during the development of ARs agonists and antagonists as therapeutic 
agents is the poor selectivity between differentreceptorssubtypes[4]. For this reason,many efforts 
have been madeto elucidate the molecular basis of ARs ligands selectivity, and several 
structure-activity relationship (SAR) models have been developed for selective ligandsof all the four 
subtypes [1,2,5–14]. 
With the increasing availability of structural information (mainly from mutagenesis, 
X-ray,andcryo-EM approaches[15]) in the last few years,light has been shed on the origin of 
selectivity onARs.Recently, the A1AR inactive (PDB, Protein Data Bank,code 5UEN [16] and 5N2S 
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[17]) and active (PDB code 6D9H [18]) structures have been solved. Interestingly, in [17], Cooke and 
colleagues obtained the X-ray crystal structure of A1 and A2A Ars,in a complex with the same 
xanthine ligand PSB36, providing insight about the selectivity.There are several structural 
differences between A1AR and A2AAR. The second extracellular loop (ECL2), in particular, is more 
folded in A1ARand orients perpendicularly to the plane of the membrane,while in A2A ARit forms a 
longer helix,which is parallel to the lipid bilayer. This difference is probably due to the presence of 
two disulfide bondsuniquely present in A2AR. Indeed,the bond between Cys71 and Cys159 
anchorsECL2 to ECL1,while the bond between Cys74 and Cys146 tethers TM3 to ECL2.The class A 
conserved disulfide bonds between Cys80 and Cys169 is present in both the two subtypes.These 
differences in the disulfide bonds likely contribute to the outward movement of the top of 
transmembrane helix 2 (TM) in the inactive A1AR (Figure 1). 
Further divergence involves TM7, which is shifted outward compared to A2AAR, due to the 
shorter ECL3, andTM6 slightly shifted inward in A1AR. These rearrangements, in turn, affect the 
orthosteric site of A1AR, which is wider than A2AAR. Interestingly, the key residues in the orthosteric 
site of the two receptors are conserved and drive the same binding mode of the antagonist PSB36 
(Figure 1). More precisely, the xanthine scaffold forms two hydrogen bonds with Asn254 (A1AR, 
Asn253 in A2A AR) and a π- π stacking with Phe171 (A1AR, Phe168 in A2AAR). Nevertheless, Asn254 
(A1AR) is located in the binding site deeper than Asn253 in A2AAR, and the xanthine ligand is 
consequently positioned deeply in the orthosteric site (Figure 1). 
 
Figure 1. Comparison of A1ARand A2AAR structures(A) Superposition of the crystal structure of the 
inactive A1 (orange)and A2A (cyan) adenosine receptors (Ars) (PDB code 5N2S and 5N2R 
respectively). (B) Superposition of the same xanthine ligand PSB36 in the two aforementioned crystal 
structures. 
Despite the huge help provided from high-resolution structural biology techniques, certain 
selectivity profiles cannot be only rationalized by the mere coordinates of bound state or “final” 
state. Ligand recognition is an articulated mechanism in which many variables may play a relevant 
role and over the last few years, there has been rising attention in the understanding of binding 
kinetics at GPCRs and its determinant role to successfully target this class of proteins[19]. 
In the present study, we used supervised molecular dynamics (SuMD) simulations toshed light 
on the molecular basis of the selectivity of three different ligands to A1AR and A2AAR, not only 
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considering the bound states, but also the possible different recognition mechanism preceding the 
final orthosteric site and the role of the solvent. We focus our attention on three antagonists:the 
A2AAR selective antagonists Z48 (Ki 16.9 nM in A2AAR and 1345.7 nM in A1AR)[20]; the A1AR 
selective antagonist LC4 (Ki 16,800 nM in A2AAR and 89 nM in A1AR)[21]; and the nonselective 
antagonist caffeine (Figure 2).SuMD[22,23] is a molecular dynamics (MD) approach that allows for 
the study of molecular recognition processes in a fully atomistic way, in the nanosecond timescale, 
without introducing any energetic biases. 
 
Figure 2. The three ligands considered in the present study. (A) Caffeine, a non-selective ARs 
antagonist. (B) LC4, an A1-AR selective antagonist. (C) Z48, an A2A-AR selective antagonist. 
2. Materials and Methods 
2.1. System Setup 
The crystal structures of the two receptors were retrieved from PDB (the PDB code is 5N2S for 
A1-AR and 5NM4 forA2A-AR). Systems preparation was performed using a Molecular Operating 
Environment (MOE)) suite (Chemical Computing Group ULC, Molecular Operating Environment 
(MOE), 2019.01. 1010 Sherbrooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2019)[24]for 
protein preparation (removal of crystallographic water molecules, ions, and other solvent molecules, 
selection of the highest occupancy for each residue, assignment of the correct protonation state at pH 
7.4). Systems preparation for the molecular dynamics simulations was carried out using VMD [25]. 
The protein was explicitly solvated in a water box with the borders placed at a distance of 15 Å from 
any protein atom, the water model used was TIP3P[26]. The system charge was neutralized to a 
concentration of 0.154M using Na+/Cl−. The lipid bilayer consisted of phosphatidylcholine (POPC) 
units. 
The sodium ionwithin the TMD allosteric site of A2A-AR was retained, andit was also placed by 
superposition in A1-AR. 
2.2. Equilibration of the System 
All the simulations were performed with a CHARMM36 force field [27] and using ACEMD2 
[28].Ligands parameters were retrieved from Paramchem[29], a web interface for the assignment of 
parameters based on the CGenFF[30] force field. 
The system energy was minimized in 1500 steps using the conjugate-gradient method, then the 
equilibrationof the system was done in four steps. The first one consistedof 5 ns of NPT simulation 
with harmonic positional constraints of 1 kcal mol−1Å−2 on each atom of the protein and the lipid 
bilayer. The second step consisted in 10 ns of NPT simulation with harmonic positional constraints 
of 1 kcal mol−1Å−2only on eachprotein atom and on the phosphorus atom of the POPC units, the third 
step consisted in 5 ns of NPT simulation with harmonic positional constraints of 1 kcal mol−1Å−2only 
on the alpha carbons of the protein, and the last step consisted in 50ns of NVT simulation without 
any constraints. 
For the productive simulations,the temperature wasmaintained at 310 K using the Langevin 
thermostat, with a low dumping of 1 ps−1. The pressure was set at 1 atm using the Berendsen 
barostat[31]. The particle-mesh Ewald (PME) method was used to calculate the electrostatic 
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interactions with a 1 Å grid[32]. A 9.0 Å cutoff was applied for long-term interactions.The M-SHAKE 
algorithm was applied to constrain the bond lengths involving hydrogen atoms. 
At the end of the equilibration, several parameterswere calculated to assess the stability of the 
system:theroot mean square deviation (RMSD) of the alpha carbons of the protein,the root mean 
square fluctuation (RMSF) of each protein residue,the volume of the cell (which should tend to a 
plateau in the NPT ensemble),and the area per lipid(APL)for each membrane layer (calculated 
usingGridMAT-MD [33]). We also computed the volume of the orthostericsiteduring the 
equilibration using POVME [34]. Figure S1 (A2A-AR) and Figure S2 (A1-AR) report the analysis 
performed during the equilibration of the system. In both the two systems, the protein reached a 
stable conformation (RMSD of the protein Cα (panel A, figure S1 and S2) stably below 2 Å for 
A2A-AR and below 3 Å for A1-AR). The volume of the orthosteric site reached a plateau in both cases 
(Panel B, figure S1 and S2). The most flexible parts of the protein, as expected, are the loops. Indeed, 
the RMSF of these regions is higher than the TMs (panels C and D, figure S1 and S2). 
As shown in Figure S5, the orthosteric site of A1-AR appears to be deeper than A2A-AR, due to a 
cleft between TM5 and TM6. The APL and the volumetric analysis are reported in Figure S3 (A1-AR) 
and Figure S4 (A2A-AR). For both systems, the cell volume reached stable values. 
2.3. Supervised Molecular Dynamics Simulations 
SuMD[22,23] is a molecular dynamics (MD) approach that allows for the investigation of 
molecular recognition processes in a fully atomistic way, in the nanosecond timescale, without 
introducing any energetic bias (Figure 3).Ligands were placed 35 Åaway from the 
protein.EachSuMD step was set to 600 ps. During each SuMD step, the distance between the center 
of mass of the binding site (defined by a series of residues) and the center of mass of the ligand is 
monitored. These dataare thenfitted, and if the slope of the interpolating linear function is negative, 
then the coordinates and the velocities are used for the successive time window, otherwise, the last 
time window is simulated again reassigning the velocities (this reassignment of the velocities is 
intrinsic in the use of Langevin thermostat).If the condition fails 30 consecutivetimes, then the 
simulation is stopped. Otherwise, the algorithm continues until the distance between the two centers 
of mass is below the threshold of 5Å; at this point, the supervision is turned off and 30 short classical 
MD simulations are performed, switching on the supervision if the distance between the centroids 
becomesgreater than 5Å.At the end of the SuMD process, the trajectoryis prolonged for 25 ns of 
classical MD simulation. 
 
Figure 3. Representation of a binding event sampled by a supervised molecular dynamics (SuMD) 
simulation. After each reported step, the distance between the ligand and the binding site decreases. 
In less than (merged) 50 ns, a binding event was sampled. 
Twenty simulations were performed for each of the six systems(Z48/A1AR, Z48/A2AAR, 
LC4/A1AR, LC4/A2AAR, Caffeine/A1AR, Caffeine/A2AAR). Only the simulationsthat sampled the 
ligand reaching the orthosteric site and interacting with the classic fingerprint of these class of 
ligands (Figure S6) were here reported (e.g., one replica for each system, excepted LC4/A1AR for 
which two replicas were analyzed).For each system, the reasonsfor failure are similar. In most cases, 
the ligands interact strongly with the residues of the ECLs, and do not reach the binding site. In a 
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few cases, the ligands only partially reach the orthosteric site. Finally, in other rare cases, the ligands 
get stuck between the protein and the membrane. 
2.4. Trajectories Analysis 
The SuMD trajectories were analyzed using anin-house python tool (described in [35]) that 
provides information on the geometry and the energetic of the system. The output consists of a 
per-residue analysis of the electrostatic and van Der Waals contributions to the protein-ligand 
interactions; a representation of the distance between the center of mass of the ligand and the center 
of mass of the binding site as a function of time; a global energetic evaluation of the system as a 
function of the aforementioned distance. This analysis allowscomparing the energetic profile of two 
systemsboth in a general way and, through the per-residue analysis (i.e., it is possible to evaluate 
which ligand has better interaction with some specific amino acids of interestover the time). 
Three replicas of 50 ns were performed on the apo form of A1-AR and A2A-AR, after the 
equilibration stage described before. These three replicas were merged and analyzed by 
AquaMMapS[36]. 
3. Results 
3.1. SuMD Binding of the A1AR Nonselective Antagonist Caffeine 
According to the SuMD simulations(Figures S7,S8;Video 1 for A1AR and Video 2 for AA2AAR in 
the Supplementary Information),the nonselective antagonist caffeineestablishes intermediate 
interactions with the extracellular vestibule of A1AR and A2AAR, before reaching the orthosteric site. 
The most stable bound configurations sampled on A1AR and A2AAR differed for theorientation of 
the xanthine ring (Figure S9). On A2AAR, caffeine pointed the N7-methyl toward Asn253, while in 
A1AR it was rotated by 180°, with the N3 methylinthe proximity of Asn254. Notably, both these two 
conformations have been experimentally observed in X-ray crystal structuresofA2AAR 
[17].Fluctuations of the ligand in both orthosteric sites and the transient nature of the interactions are 
easily depicted in the energy interaction landscapes (Panels A,S7,S8) in which the points are 
particularly scattered over the distance between the centers of mass of the ligand and the orthosteric 
site. 
3.2. SuMD Binding of the A2AAR Selective Antagonist Z48 
FiguresS10,S11reportthe analysis of Z48/A1ARand Z48/A2AAR, including 25 ns of classic MD 
simulations performed at the end of each SuMD simulation (Videos 3,4in the Supplementary 
Information). 
For what concerns the SuMD trajectory of Z48 on A1AR, notable electrostatic repulsion took 
place between the ligand and Lys168, Lys173, and Lys265, before the ligand reached the orthosteric 
site, as clearly observable in the per-residue electrostatic interaction energy plot (Panel C,S10).These 
residues are positioned on the ECLs (Lys168 and Lys173 on ECL2, andLys265 on ECL3). As a result, 
in A1AR, Z48 did not adopt the binding fingerprint of the ARs antagonists (e.g.,only one hydrogen 
bond with Asn254 out of two was formed). Moreover, this binding mode wasunstable over the 25 ns 
of classic MD simulations.Interestingly, the terminal amine group of the ligand strongly interacts 
with Glu170 (Leu167 in A2AAR).Figure 4 reports the binding modes of Z48 at the end of the SuMD 
simulation on A1AR (the binding mode at the end of the 25 ns of classic MD simulation is shown in 
Figure S12) and A2A-AR (at the end of the 25 ns of classic MD simulation), respectively. 
Moving to the binding simulations of Z48 toA2AAR, two SuMDreplicas led to the classic binding 
mode of the ARs antagonists.The π-πstacking with Phe168 was present, along with the hydrogen 
bonds with Asn253 and with Glu169. Both binding modeswere stable during 25 ns of classic MD 
simulations (Figure S11, Panel C,D, Figure 4). No significantprotein-ligand electrostatic 
repulsionswereobserved. The narrow funnel-like interaction energy profile of the ligand in the 
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orthostatic also suggested a good complementarity of the ligand in the pocket, and a rapid reaching 
of a stable bound state. 
 
Figure 4. Binding mode of Z48 within the binding site of A1-AR on the left-hand side, and within the 
binding site of A2A-AR on the right-hand side (superposition of the two simulations analyzed). For 
A1AR, the binding mode is reported at the end of the SuMD simulation. For A2AAR, the two poses at 
the end of the classic MD simulation are reported. 
3.3. SuMD Binding of the A1AR Selective Antagonist LC4 
With regards to LC4, two SuMDreplicas led to different binding modes of LC4 into the A1AR 
orthosteric site. During Replica 1, the ligand formed a complex characterized by the xanthine 
scaffold positioned in the orthosteric binding site,and the N8-substituent pointed outward the 
receptor (Figure 5). A hydrogen bond with Asn254 and hydrophobic contacts with Phe171 occurred 
(Figure 6A). Interestingly, the LC4 oxygen atom in the N8 substituent interacted with and stabilized 
water molecules in the proximity of the Phe171 backbone, a hydrated spot on ECL3, according to the 
AquaMMapS analysis (Figure 6A). 
In the case of A2AR, the xanthine scaffold reached the orthostericsite rotated by 180° compared 
to the binding mode adopted in A1AR (Figure 6B) and with an unfavorable geometry for hydrogen 
bonding with Asn253. In both of these two binding modes (Figure S13 and Figure S14), LC4 did not 
interactwithconserved glutamate Glu172 (A1AR)orGlu169 (A2AAR). 
During SuMDReplica 2 on A1A, LC4 experienced a two-step binding (Figure 6). First, the 
antagonist entered the orthosteric site pointing the methylphenyl group into a hydrophobic pocket 
located between TM2 and TM3. This cryptic pocket is not present in A2AR in light of bulkier residues 
and a higher degree of packing between the helixes (Figure 6B). From this metastable configuration, 
LC4 moved deeper into the orthosteric site and engagedAsn254 and Glu172 in hydrogen bonds 
(Figure 6). In this binding mode, the ligand inserted the N8-substituent inside a further cryptic 
pocket between TM5 and TM6 (Figure 6C,D), which is delimited by the “toggle switch” residue 
W247 [15], and the residues Ile95 and Phe253, being part of the conserved class A structural motif 
PIF [37]. Notably, this hydrophobic sub-pocket was occupied by likely “unhappy” water molecules 
during simulations of the apo-A1R (Figure 6A). 
The video of these three simulations can be found in Supplementary MaterialsVideo 5 and 
Video 6 for the two simulations of LC4/A1AR, and Video 7 for the simulation of LC4/AA2AAR. 
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Figure 5. Binding mode of ligand LC4. A1AR on the left and A2AAR on the right. 
 
Figure 6. (A) Hydrated spots within A1AR with AquaMMapSoccupancy > 10%. The cryptic pocket 
between TM5 and TM6, as well as the spot nearby the Phe171 backbone, are indicated; (B) 
comparison between A1AR (orange) and A2AAR(cyan) at the level of TM2 and TM3—a sub-pocket 
formed only in A1AR during MD simulations, due to different residues and interhelical packing; (C) 
and (D) two side views of the two superimposed binding steps of LC4 (green stick) to A1AR. 
Hydrophobic contacts are shown as cyan transparent surfaces. 
4. Discussion 
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Here we present results from SuMD simulations performed to shed light on the selectivity 
displayed by LC4 and Z48, two antagonists of A1AR and A2AAR, respectively. The nonselective 
antagonist caffeine was also dynamically docked to the two ARs subtype.Caffeine, which is in a 
weak binder(micromolar range [38]) of all the ARs, experienced more than one binding mode, in line 
with our previous simulations[22]and experimental observation [17]. 
SuMD binding of the selective A2AAR antagonistZ48 on A1-AR and A2AAR suggested different 
interaction patterns along the pathways. Z48 experienced unfavorable electrostatic interactions 
between positively charged A1AR residues Lys168, Lys173 (ECL2), and Lys265 (ECL3), and the 
ligand charged amine on the N8-substituent. Such transitory states did not take place during 
binding to A2AAR, as no significant electrostatic repulsions were computed at the extracellular 
vestibule. Interestingly, A2AAR bears Ala265 instead of Lys265 on the ECL3, while Lys168 and 
Lys173 (ECL2) are farther from the binding site, compared to A1AR. This is consistent with 
mutagenesis studies that demonstrated the importance of these lysine residues forthe binding of 
several A1AR ligands [39–41]. On A2AAR, Z48 reachedthe orthosteric site producing the classic 
interactions fingerprint of the ARs antagonists. On A1AR, on the other hand,the ligand sampled a 
different binding mode. Moreover, the A1AR residue Glu170 (Val167 in A2AAR) strongly interacted 
with the charged terminal amine of the ligand, stabilizing this alternative binding mode. Z48 was 
proposed to bind to A2AR overcoming low enthalpy transition state(s)[40]. From this standpoint, the 
unfavorable electrostatic interactions with ECL2 could implicate a slower binding toA1AR, and 
therefore a kinetic selectivity for A2AR. 
SuMD simulations of the antagonist LC4 proposed two possible binding modes that could 
drive selectivity. It is possible that the ligand binds A1AR and A2AAR with the same conformation, 
but differently interacting with water molecules nearby ECL3. From this standpoint, and in analogy 
with [41],we propose these “happy” water molecules contribute to the ligand stabilization in A1AR 
(Figure S16), but not in A2AR (FigureS17). An alternative and unique LC4 binding mechanism was 
sampled only on A1AR, with a metastable state before the final complex formation. Along this 
pathway, two cryptic hydrophobic pockets (between TM2 and TM3 and between TM5 and TM6) 
allowed the N8-substituent of the ligand to correctly orient first, and then engage key residues for 
the receptor activation (the “toggle switch” Trp247, Ile95, and Phe253, which are part of the 
conserved class A motif PIF). Notably, the cryptic pocket between TM2 and TM3 has recently been 
proposed as a determinant for A1AR selectivity displayed by the triazolotriazine antagonist LUF5452 
[42,43]. 
5. Conclusions 
Understanding the selectivity of GPCRs ligands is an important task in drug design. This study 
supports the emerging idea that selectivity is driven by a plethora of phenomena, other than the 
protein-ligand interactions in the bound state. Receptor-ligands recognitions are multistep events 
modulated by intermediate interaction along withthe (un)binding paths. This picture may be further 
complicated by the presence of stable water molecules, whichcan have a tremendous impact on 
stabilizing or destabilizing an orthosteric complex. To consider different aspects that may affect the 
selectivity on A1AR and A2AAR, we used SuMD simulations to investigate the recognition of thee 
different antagonists. Overall, our results suggest that kinetic selectivity may favor the binding of 
Z48 to A2AAR over LC4. A different scenario was observed for A1AR, the recognition trajectories 
highlighted the key role of water molecules in the binding mode of LC4, which is favored by two 
hidden sub pockets within A1AR. 
Supplementary Materials: The following are available online at www.mdpi.com/2218-273X/10/5/732/s1, Figure 
S1: A2AAR, protein analysis during the equilibration stage,Figure S2: A1AR, protein analysis during the 
equilibration stage. Figure S3:A1AR system, cell volume analysis and membrane analysis. Figure S4: A2AAR 
system, cell volume analysis and membrane analysis. Figure S5: Volumetric analysis (using POVME) of the 
orthosteric site of A1AR and A2AAR. Figure S6: X-Ray structure of  A2AAR in complex with caffeine and with 
ZMA. Figure S7: Analysis of the SuMD trajectory of binding for caffeine on A1AR. Figure S8: Analysis of the 
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SuMD trajectory of binding for caffeine on A2AAR. Figure S9: Caffeine binding mode of caffeine within the 
binding site of A1AR and A2AAR. Figure S10: Analysis of the Z48 SuMD binding trajectoryto A1AR. Figure 
S11:Analysis of the SuMD trajectory of binding for Z48 on A2AAR. Figure S12: Binding mode of Z48 in A1AR at 
the end of the 25ns of classic MD. Figure S13 Analysis of the SuMD trajectory of binding for LC4 on A1AR. 
Figure S14 Analysis of the SuMD trajectory of binding for LC4 on A2AAR. Figure S15 Analysis of the SuMD 
trajectory of the alternative binding for LC4 on A1AR. Figure S16: Interaction between LC4 and water molecules 
inA1AR. Figure S17:Interaction between LC4 and water molecules in A1AR and A2AAR.Video S1:Caffeine 
binding pathway against A1-AR., Video S2: Caffeine binding pathway against A2A-AR, Video S3: Z48 binding 
pathway against A1-AR. Video 4: Z48 binding pathway against A2A-AR.Video 5: LC4 binding pathway against 
A1-AR,binding mode 1.Video 6: LC4 binding pathway against A1-AR, binding mode 2.Video 7: LC4 binding 
pathway against A2A-AR. 
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